Loading company…
Hamburg-based Topas Therapeutics develops nanoparticle delivery therapies aimed at autoimmune diseases and allergies.
Founded in 2013 and headquartered in Hamburg, Germany, Topas Therapeutics GmbH develops nanoparticle-based delivery of biologic medicines to modulate the immune response in autoimmune diseases and allergies. It raised USD 18.00 mn in Series B funding on June 29, 2021, co-led by Boehringer Ingelheim Venture and Evotec SE, and has completed four deals at a current valuation of USD 101.41 mn. In January 2026, The Tofoo Company Limited, a portfolio company of Comitis Capital, agreed to acquire the company from existing investors including Epidarex Capital and Boehringer Ingelheim Venture, with completion expected that month.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in